gemlapodect

Gemlapodect (NOE-105) is a novel, potent, and selective small molecule inhibitor of phosphodiesterase 10A (PDE10A), developed for the treatment of Tourette syndrome and childhood onset fluency disorder (stuttering). It acts as a dopamine modulator by inhibiting PDE10A, an enzyme highly expressed in medium spiny neurons of the striatum. This mechanism allows for modulation—rather than blockade—of dopamine D2 receptor signaling, potentially reducing motor and vocal tics in Tourette syndrome and improving speech fluency in stuttering. Unlike traditional antipsychotics used for these indications, gemlapodect has shown no significant metabolic side effects such as weight gain or changes in blood glucose or lipids. The drug is administered orally as hard gelatin capsules and is currently in Phase 2 clinical development. Gemlapodect was originally licensed from Roche to Noema Pharma[1][2][5][6][7].

Other names

NOE-105NOE105NOE 105gemlapodect